10x Genomics: Lower Cost Innovation May Drive A Rebound
Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...
Hosted on MSN1mon
10x Genomics sees robust growth across platforms in Q4 2023
10x Genomics delivered strong Q4 2023 results with substantial contributions from Xenium and Visium platforms. As the company enters 2024, its focus on expanding product adoption while managing ...
Yahoo Finance25d
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology. 10x ...
Business Insider25d
10x Genomics unveils roadmap at AGBT general meeting
10x Cloud Analysis for Large Studies; Visium HD 3′ for high resolution, species-agnostic spatial profiling; Visium HD Cell Segmentation for morphology-guided spatial transcriptomics; Xenium RNA ...
Nasdaq25d
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
These capabilities will be available to support both the Chromium and Visium platforms ... tissue organization and function. Xenium RNA+Protein Multiomics: 10x Genomics shared plans to enable ...
Fox 5 San Diego25d
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
The forthcoming Visium HD 3' assay is a reverse transcription ... sections at single-cell-scale resolution. Xenium RNA+Protein Multiomics: 10x Genomics shared plans to enable simultaneous ...